• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by National Vision Holdings Inc. (Amendment)

    2/9/24 3:47:48 PM ET
    $EYE
    Ophthalmic Goods
    Health Care
    Get the next $EYE alert in real time by email
    SC 13G/A 1 nati23a2.htm nati23a2.htm - Generated by SEC Publisher for SEC Filing  

     

            CUSIP NO.  63845R107                        13G                            Page 1 of 7

     

                                                                                       UNITED STATES

                                                                  SECURITIES AND EXCHANGE COMMISSION

                                                                              Washington, D.C. 20549

     

                                                                                        SCHEDULE 13G

     

                                                           Under the Securities Exchange Act of 1934

                                                                                  (Amendment No. 2)*

     

                                                                      National Vision Holdings, Inc.

                                                                                    (Name of Issuer)

     

                                                             Common Stock, par value $0.01 per share

                                                                      (Title of Class of Securities)

     

                                                                                           63845R107

                                                                                      (CUSIP Number)

     

                                                                                   December 31, 2023

                                             (Date of Event Which Requires Filing of this Statement)

     

              Check the appropriate box to designate the rule pursuant to which this Schedule is

              filed:

     

              [X] Rule 13d‑1(b)

              [ ] Rule 13d‑1(c)

              [ ] Rule 13d‑1(d)

     

              *The remainder of this cover page shall be filled out for a reporting person's

              initial filing on this form with respect to the subject class of securities, and

              for any subsequent amendment containing information which would alter the

              disclosures provided in a prior cover page.

     

              The information required in the remainder of this cover page shall not be deemed to

              be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934

              ("Act") or otherwise subject to the liabilities of that section of the Act but

              shall be subject to all other provisions of the Act (however, see the Notes).

     


     
     

     

            CUSIP NO.  63845R107                        13G                            Page 2 of 7

     

              1.   NAMES OF REPORTING PERSONS.    

     

                         ClearBridge Investments, LLC  

     

              2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

                         (a)

                         (b) X

     

              3.   SEC USE ONLY

     

              4.   CITIZENSHIP OR PLACE OF ORGANIZATION

     

                         Delaware

     

              NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

                         5.   SOLE VOTING POWER

     

                                    (See Item 4)

     

                         6.   SHARED VOTING POWER

     

                                    (See Item 4)

     

                         7.   SOLE DISPOSITIVE POWER

     

                                    (See Item 4)

     

                         8.   SHARED DISPOSITIVE POWER

     

                                    (See Item 4)

     

              9.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

                        4,329,234

     

              10.  CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

                         CERTAIN SHARES [ ]

     

              11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

                         5.5%

     

              12.  TYPE OF REPORTING PERSON

     

                         IA, OO (See Item 4)

     


     
     

     

     

            CUSIP NO.  63845R107                        13G                            Page 3 of 7

     

              Item 1.

     

              (a)   Name of Issuer

                          National Vision Holdings, Inc.

     

              (b)   Address of Issuer's Principal Executive Offices

     

                          2435 Commerce Ave

                            Building 2200

               Duluth, GA 30096-4980

                           

              

              Item 2.

     

              (a)   Name of Person Filing

     

                          ClearBridge Investments, LLC

     

              (b)   Address of Principal Business Office or, if none, Residence

     

               620 8th Ave.

               New York, NY 10018

     

              (c)   Citizenship

     

                          Delaware

     

              (d)   Title of Class of Securities

     

                          Common Stock, par value $0.01 per share

     

              (e)   CUSIP Number

     

                          63845R107

     


     
     

     

     

            CUSIP NO.  63845R107                        13G                            Page 4 of 7

     

              Item 3. If this statement is filed pursuant to §§240.13d‑1(b) or 240.13d‑2(b) or (c),

                              check whether the person filing is a:

                              (a) [ ]  Broker or dealer registered under section 15 of the Act (15 U.S.C. 8o).

     

                              (b) [ ]  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

                              (c) [ ]  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C.

                                                78c).

     

                              (d) [ ]  Investment company registered under section 8 of the Investment Company

                                                Act of 1940 (15 U.S.C 80a ‑8).

     

                              (e) [X]  An investment adviser in accordance with §240.13d‑1(b)(1)(ii)(E);

     

                              (f) [ ]  An employee benefit plan or endowment fund in accordance with

                                                §240.13d‑1(b)(1)(ii)(F);

     

                              (g) [ ]  A parent holding company or control person in accordance with

                                                §240.13d‑1(b)(1)(ii)(G);

     

                              (h) [ ]  A savings associations as defined in Section 3(b) of the Federal

                                                Deposit Insurance Act (12 U.S.C. 1813);

     

                              (i) [ ]  A church plan that is excluded from the definition of an investment

                                                company under section 3(c)(14) of the Investment Company Act of 1940

                                                (15 U.S.C. 80a‑3);

     

                              (j) [ ]  A non‑U.S. institution in accordance with §240.13d‑1(b)(ii)(J);

     

                              (k) [ ]  Group, in accordance with §240.13d‑1(b)(1)(ii)(K).

     

                              If filing as a non‑U.S. institution in accordance with §240.13d‑1(b)(1)(ii)(J),

                              please specify the type of institution

     

              Item 4. Ownership

     

              The securities reported herein are beneficially owned by one or more open‑end investment

              companies or other managed accounts that are investment management clients of ClearBridge

         Investments, LLC ("CIL"), an indirect wholly owned subsidiary of Franklin Resources, Inc.

         ("FRI"). When an investment management contract (including a sub‑advisory agreement)

         delegates to CIL investment discretion or voting power over the securities held in the

         investment advisory accounts that are subject to that agreement, FRI treats CIL as having

         sole investment discretion or voting authority, as the case may be, unless the agreement

         specifies otherwise. Accordingly, CIL reports on Schedule 13G that it has sole investment

         discretion and voting authority over the securities covered by any such investment

         management agreement, unless otherwise noted in this Item 4. As a result, for purposes of

         Rule 13d‑3 under the Act, CIL may be deemed to be the beneficial owner of the securities

         reported in this Schedule 13G.

     

              Beneficial ownership by investment management subsidiaries and other affiliates of FRI

              is being reported in conformity with the guidelines articulated by the SEC staff in

              Release No. 34‑39538 (January 12, 1998) relating to organizations, such as FRI, where

              related entities exercise voting and investment powers over the securities being

              reported independently from each other. The voting and investment powers held by CIL are

              exercised independently from FRI (CIL’s parent holding company) and from all other

              investment management subsidiaries of FRI (FRI, its affiliates and investment management

              subsidiaries other than CIL are, collectively, “FRI affiliates”). Furthermore, internal

              policies and procedures of CIL and FRI affiliates establish informational barriers that

         prevent the flow between CIL and the FRI affiliates of information that relates to the

         voting and investment powers over the securities owned by their respective investment

         management clients. Consequently, CIL and the FRI affiliates report the securities over

         which they hold investment and voting power separately from each other for purposes of

         Section 13 of the Act.


     
     

     

            CUSIP NO.  63845R107                        13G                            Page 5 of 7

     

              Charles B. Johnson and Rupert H. Johnson, Jr. (the "Principal Shareholders") each own in

              excess of 10% of the outstanding common stock of FRI and are the principal stockholders

              of FRI. However, because CIL exercises voting and investment powers on behalf of its

              investment management clients independently of FRI affiliates, beneficial ownership of the

              securities reported by CIL is not attributed to the Principal Shareholders. CIL

              disclaims any pecuniary interest in any of the securities reported in this Schedule 13G. 

              In addition, the filing of this Schedule 13G on behalf of CIL should not be construed as

              an admission that it is, and it disclaims that it is, the beneficial owner, as defined

              in Rule 13d‑3, of any of such securities.

     

              Furthermore, CIL believes that it is not a "group" with FRI affiliates, the Principal

              Shareholders, or their respective affiliates within the meaning of Rule 13d‑5 under the

              Act and that none of them is otherwise required to attribute to any other the

              beneficial ownership of the securities held by such person or by any persons or

              entities for whom or for which CIL or the FRI affiliates provide investment management

              services.

     

                  (a)     Amount beneficially owned:

     

                                  4,329,234

     

                  (b)     Percent of class:

     

                                  5.5%

     

                  (c)     Number of shares as to which the person has:

     

                          (i)    Sole power to vote or to direct the vote

     

                                        ClearBridge Investments, LLC:                                 4,328,380

     

                        (ii)    Shared power to vote or to direct the vote

     

                                        0

     

                      (iii)    Sole power to dispose or to direct the disposition of

     

                                        ClearBridge Investments, LLC:                                 4,329,234

     

                        (iv)    Shared power to dispose or to direct the disposition of

     

                                        0

     

              Item 5. Ownership of Five Percent or Less of a Class

     

                              If this statement is being filed to report the fact that as of the date hereof

                              the reporting person has ceased to be the beneficial owner of more than five

                              percent of the class of securities, check the following [ ]. 

     

              Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

                              The clients of ClearBridge Investments, LLC, including investment companies

                              registered under the Investment Company Act of 1940 and other managed accounts,

                              have the right to receive or power to direct the receipt of dividends from, and

                              the proceeds from the sale of, the securities reported herein.

     

                

                  

                

     

           

     

     

     


     
     

     

    CUSIP NO.  63845R107                            13G                            Page 6 of 7

     

              Item 7. Identification and Classification of the Subsidiary Which Acquired the

                              Security Being Reported on By the Parent Holding Company

     

                              Not Applicable

     

              Item 8. Identification and Classification of Members of the Group

     

                              Not Applicable

     

              Item 9. Notice of Dissolution of Group

     

                              Not Applicable

     


     
     

     

     

            CUSIP NO.  63845R107                        13G                            Page 7 of 7

     

              Item 10. Certification

     

              By signing below I certify that, to the best of my knowledge and belief, the securities

              referred to above were acquired and are held in the ordinary course of business and were

              not acquired and are not held for the purpose of or with the effect of changing or

              influencing the control of the issuer of the securities and were not acquired and are

              not held in connection with or as a participant in any transaction having that purpose

              or effect, other than activities solely in connection with a nomination under § 240.14a-11

     

             

     

                                                                                      SIGNATURE

     

              After reasonable inquiry and to the best of my knowledge and belief, I certify that the

              information set forth in this statement is true, complete and correct.

     

              Dated:  February 2, 2024

     

              ClearBridge Investments, LLC

           

     

              By:    /s/BRIAN R. MURPHY

                            ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑

                            Brian R. Murphy

                            Chief Compliance Officer of ClearBridge Investments, LLC    

     

     

     

     

        

     

     

     

     

    Get the next $EYE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EYE

    DatePrice TargetRatingAnalyst
    5/9/2025$21.00Neutral → Buy
    Citigroup
    5/7/2025Underperform → Buy
    BofA Securities
    10/17/2023$25.00 → $16.00Buy → Neutral
    Goldman
    7/27/2023$28.00 → $22.00Buy → Neutral
    Citigroup
    7/27/2023$30.00 → $21.00Overweight → Equal Weight
    Wells Fargo
    5/2/2023Overweight → Equal Weight
    Barclays
    3/31/2023$23.00Hold → Buy
    Loop Capital
    1/17/2023Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $EYE
    Financials

    Live finance-specific insights

    See more
    • National Vision Holdings, Inc. Reports First Quarter 2025 Financial Results

      Successful Execution of New Transformation Initiatives and Cost Reduction Actions Delivered Strong First Quarter First quarter 2025 highlights compared to Q1 2024: Net revenue from continuing operations of $510.3 million, an increase of 5.7% Comparable store sales growth of 4.1% and Adjusted Comparable Store Sales Growth of 5.5% represented the 9th consecutive quarter of positive growth Income from continuing operations of $14.2 million, Diluted EPS from continuing operations of $0.18 Adjusted Operating Income from continuing operations of $41.3 million Adjusted Diluted EPS from continuing operations of $0.34 Raises fiscal 2025 outlook National Vision Holdings, Inc. (NASDAQ:E

      5/7/25 6:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Holdings, Inc. Announces First Quarter 2025 Earnings Release and Conference Call

      National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") will report its first quarter 2025 financial results before the market opens on Wednesday, May 7, 2025, and will host a conference call at 8:30 a.m. Eastern Time. To pre-register for the conference call and obtain a dial-in number and passcode, please refer to the "Investors" section of the Company's website at www.nationalvision.com/investors. A live audio webcast of the conference call, together with related materials, will be available online in the "Investors" section of the Company's website. A replay of the audio webcast will be available shortly after the broadcast. About National Vision Holdings, Inc.

      4/24/25 8:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Holdings, Inc. Reports Fourth Quarter and Fiscal 2024 Financial Results

      Strong Fourth Quarter Results Reflect Successful Execution on Store-Level Transformation Initiatives Introduced Targeted Initiatives to Broaden Appeal and Expand Customer Base Actions Taken to Reduce Costs and Strengthen Profitability Fourth quarter 2024 highlights: Net revenue from continuing operations of $437.3 million, an increase of 3.9% as compared to Q4 2023 Comparable store sales growth of 2.6% and Adjusted Comparable Store Sales Growth of 1.5% as compared to Q4 2023 Net loss from continuing operations of $(29.4) million, Diluted EPS from continuing operations of $(0.37) Adjusted Operating Income from continuing operations increased to $3.2 million from $(2.7) mill

      2/26/25 6:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Chief Technology Officer Acharya Ravi sold $225,060 worth of shares (12,000 units at $18.75), decreasing direct ownership by 51% to 11,700 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      5/14/25 4:37:10 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Chief Legal & Strategy Officer Brandman Jared converted options into 1,889 shares and covered exercise/tax liability with 562 shares, increasing direct ownership by 3% to 44,705 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      4/30/25 4:27:11 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Chief Brand & Mktg Officer Vandette Joseph converted options into 1,831 shares and covered exercise/tax liability with 545 shares, increasing direct ownership by 9% to 15,940 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      4/14/25 4:43:08 PM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • National Vision upgraded by Citigroup with a new price target

      Citigroup upgraded National Vision from Neutral to Buy and set a new price target of $21.00

      5/9/25 8:39:42 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision upgraded by BofA Securities

      BofA Securities upgraded National Vision from Underperform to Buy

      5/7/25 2:46:43 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision downgraded by Goldman with a new price target

      Goldman downgraded National Vision from Buy to Neutral and set a new price target of $16.00 from $25.00 previously

      10/17/23 7:19:16 AM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Leadership Updates

    Live Leadership Updates

    See more
    • National Vision Appoints Alex Wilkes as CEO

      Reade Fahs to Assume Executive Chairman Position Transition Effective August 1, 2025 National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced that its Board of Directors has appointed Alex Wilkes as the Company's next Chief Executive Officer, effective August 1, 2025, and he will join the Company's Board at that time. Mr. Wilkes succeeds Reade Fahs who will assume the role of Executive Chairman of the Board. Mr. Fahs will continue to work closely with Mr. Wilkes, ensuring a smooth transition. "National Vision has been on a journey of significant transformation for the past few years, and today I am pleased to announce the next chapter in that tran

      4/29/25 6:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Appoints Jim McGrann and Michael Nicholson to Board of Directors

      Enters into Cooperation Agreement with Engine Capital National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced the appointment of two new independent directors, Jim McGrann and Michael Nicholson to its Board of Directors (the "Board"), effective March 17, 2025. Mr. McGrann will serve on the Board's Compensation Committee and Mr. Nicholson will serve on the Board's Audit Committee and Nominating and Corporate Governance Committee. With the addition of Messrs. McGrann and Nicholson, the Board will expand from 9 to 11 members. The Board has also formed an Advisory Committee that will help oversee National Vision's ongoing transformation initiatives with

      3/17/25 4:05:00 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Appoints Christopher Laden as Chief Financial Officer

      National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced the appointment of Christopher Laden as Chief Financial Officer, effective March 31, 2025. He will succeed Melissa Rasmussen who, as previously announced, will step down from the Company, effective March 3, 2025. "We are thrilled to welcome Chris to National Vision. He has a proven track record of successfully developing finance organizations into strong cross-functional business partners by focusing on accountability, employee development, and driving efficiencies through the use of digitization. His experience in both the service and optical industries will be instrumental as we move forward

      2/26/25 5:59:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    SEC Filings

    See more
    • SEC Form 10-Q filed by National Vision Holdings Inc.

      10-Q - National Vision Holdings, Inc. (0001710155) (Filer)

      5/8/25 8:36:28 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - National Vision Holdings, Inc. (0001710155) (Filer)

      5/7/25 6:05:18 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • SEC Form DEF 14A filed by National Vision Holdings Inc.

      DEF 14A - National Vision Holdings, Inc. (0001710155) (Filer)

      4/29/25 6:22:58 AM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • National Vision Holdings, Inc. Reports First Quarter 2025 Financial Results

      Successful Execution of New Transformation Initiatives and Cost Reduction Actions Delivered Strong First Quarter First quarter 2025 highlights compared to Q1 2024: Net revenue from continuing operations of $510.3 million, an increase of 5.7% Comparable store sales growth of 4.1% and Adjusted Comparable Store Sales Growth of 5.5% represented the 9th consecutive quarter of positive growth Income from continuing operations of $14.2 million, Diluted EPS from continuing operations of $0.18 Adjusted Operating Income from continuing operations of $41.3 million Adjusted Diluted EPS from continuing operations of $0.34 Raises fiscal 2025 outlook National Vision Holdings, Inc. (NASDAQ:E

      5/7/25 6:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Appoints Alex Wilkes as CEO

      Reade Fahs to Assume Executive Chairman Position Transition Effective August 1, 2025 National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced that its Board of Directors has appointed Alex Wilkes as the Company's next Chief Executive Officer, effective August 1, 2025, and he will join the Company's Board at that time. Mr. Wilkes succeeds Reade Fahs who will assume the role of Executive Chairman of the Board. Mr. Fahs will continue to work closely with Mr. Wilkes, ensuring a smooth transition. "National Vision has been on a journey of significant transformation for the past few years, and today I am pleased to announce the next chapter in that tran

      4/29/25 6:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • National Vision Holdings, Inc. Announces First Quarter 2025 Earnings Release and Conference Call

      National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") will report its first quarter 2025 financial results before the market opens on Wednesday, May 7, 2025, and will host a conference call at 8:30 a.m. Eastern Time. To pre-register for the conference call and obtain a dial-in number and passcode, please refer to the "Investors" section of the Company's website at www.nationalvision.com/investors. A live audio webcast of the conference call, together with related materials, will be available online in the "Investors" section of the Company's website. A replay of the audio webcast will be available shortly after the broadcast. About National Vision Holdings, Inc.

      4/24/25 8:00:00 AM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Peeler D Randolph bought $264,200 worth of shares (25,000 units at $10.57) (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      8/14/24 4:27:52 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Director Hepner Virginia A bought $10,365 worth of shares (1,000 units at $10.37), increasing direct ownership by 3% to 36,635 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      8/14/24 4:26:51 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Fahs L Reade bought $299,200 worth of shares (20,000 units at $14.96), increasing direct ownership by 3% to 633,097 units (SEC Form 4)

      4 - National Vision Holdings, Inc. (0001710155) (Issuer)

      5/14/24 8:01:46 AM ET
      $EYE
      Ophthalmic Goods
      Health Care

    $EYE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

      SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

      11/14/24 12:33:08 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

      SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

      11/12/24 4:45:48 PM ET
      $EYE
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

      SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

      11/4/24 1:18:26 PM ET
      $EYE
      Ophthalmic Goods
      Health Care